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Aspergillus fumigatus is a chronic colonizer of the respiratory tract of patients with cystic fibrosis (CF). A total of 204 A. fumigatus isolates
from 36 CF patients from three different medical centers, collected over a period of four months till 9.5 years, were genotyped using the short
tandem repeat panel for A. fumigatus (STRAf assay). Four different colonization patterns were observed. Colonization patterns with only unique
genotypes were found in 36% of the patients. In contrast 17% of the patients were chronically colonized with a single genotype. The remaining
patients showed a predominant genotype or genotypes that succeed each other. In this collection no relation was found between colonization
patterns and allergic bronchopulmonary aspergillosis.
© 2008 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Aspergillus; Cystic fibrosis; Colonization; Molecular typing1. Introduction
Cystic fibrosis (CF) or mucoviscidosis is an autosomal
recessive disorder with an incidence of approximately one in
2500 live births in the Caucasian population. Mutations in the
gene encoding the cystic fibrosis transmembrane conductance
regulator (CFTR) result in dysfunction of the exocrine glands.
As a consequence of this deficient transport mechanism,
copious amounts of viscous respiratory mucus are secreted,
which is difficult to clear and provides a breeding ground for
microorganisms [1]. Early in life, CF patients become infected
with a limited spectrum of bacteria, mostly Staphylococcus
aureus and Haemophilus influenzae. As the disease progresses,⁎ Corresponding author. Department of Medical Microbiology and Infectious
Diseases, Canisius Wilhelmina Hospital, Weg door Jonkerbos 100, 6532 SZ
Nijmegen, The Netherlands. Tel.: +31 24 3657514; fax: +31 24 3657516.
E-mail address: h.v.haren@cwz.nl (H.A. de Valk).
1569-1993/$ - see front matter © 2008 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2008.10.003Pseudomonas aeruginosa becomes the most common pathogen
[2]. Aspergillus fumigatus is by far the most isolated
filamentous fungus from respiratory secretions of CF patients
and up to 57% are chronically colonized with this fungus [3]. A
commonly recognized complication of Aspergillus infection in
CF patients is allergic bronchopulmonary aspergillosis (ABPA),
with a prevalence of approximately 1 to 15% [3–5]. Although
persistent inflammation and the resulting pulmonary injury can
finally progress to fibrosis [6], knowledge about the epidemiol-
ogy of A. fumigatus in CF patients is scarce [7,8].
A better understanding of the airway colonization by
A. fumigatus in CF patients may be achieved by accurate
molecular typing of sequential isolates from sputum samples.
For A. fumigatus, several typing techniques have been described
previously, including microsatellite based fingerprinting assays.
The STRAf assay, based on nine microsatellite or short tandem
repeat (STR) markers, is a robust [9], reproducible [10] typing
technique with a high discriminatory power [11]. Thesed by Elsevier B.V. All rights reserved.
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other previously employed typing techniques, such as random
amplified polymorphic DNA (RAPD) [12] and restriction
fragment length polymorphism (RFLP) [13], which suffer from
poor interlaboratory reproducibility and subjective interpreta-
tion of the fingerprinting data [14].
Up to now, four studies comprising a total of 20 CF patients
have described the colonization pattern of A. fumigatus [15–18].
Verweij et al. [18] performed molecular typing of sequential
isolates from two patients with RAPD. With the Afut1-RFLP
method, a predominant genotype in sequential sputum samples
of one patient was detected. In another patient nine different
genotypes were seen in 12 sputum samples. Neuveglise et al.
[16] collected 412 A. fumigatus isolates from 6 patients over a
2.5-year-period. These isolates yielded 54 unique genotypes
with the Afut1-RFLP method. In all samples of the six patients,
several A. fumigatus genotypes were found, whereas two
patients harbored a predominant genotype. The two other
studies [15,17] used solely the low discriminatory molecular
typing assay RAPD, which suggested the majority of isolates to
be of the same genotype [15].
In this study we report the colonization patterns of 196
A. fumigatus genotypes in 36 different CF patients from 3
European medical centers. The isolates were collected from
sequential sputum samples and analyzed using the highly
discriminatory STRAf assay.
2. Materials and methods
2.1. Isolates
A total of 204 isolates from 36 CF patients were included in
this study. Sputum samples were collected from these patients
from 1996 through January 2008 during routine clinical visits or
during an admission to hospital because of exacerbation of their
pulmonary disease. The time period between the first and the
last A. fumigatus isolate per patient varied from four months to
nine and a half years. The numbers of isolates per patient varied
from two till 27. The patients originated from three different
centers; 100 isolates from 14 patients were obtained from the
Cystic Fibrosis Center Dekkerswald (Nijmegen, The Nether-
lands); 58 isolates from 15 patients were collected from the
University of Aachen (Aachen, Germany); another 46 isolates
from 7 patients were from the University Medical Center
Würzburg (Würzburg, Germany).
2.2. Collection of A. fumigatus isolates
Sputum samples obtained from patients were routinely
cultured on Sabouraud agar for 7 days at 30 and 35 °C.
A. fumigatus isolates were identified at the time of collection by
their macroscopic and microscopic characteristics and their
ability to grow at 48 °C. The obtained isolates were stored as
spore suspensions in regular microbial freezing broth containing
12.5% (vol/vol) glycerol at −80 °C until testing. The isolates
were revived by scraping off part of the frozen broth, plated on
Sabouraud or potato agar, and cultivated at 30 °C.2.3. STRAf assay
Genomic fungal DNA was extracted and purified from all
isolates with the MagNA Lyzer and MagNA Pure LC
Instruments (Roche Diagnostics, Almere, The Netherlands)
and PCR primers and conditions were exactly as described
before [11]. The obtained PCR fragments were diluted 30 fold
with distilled water. One μl of diluted PCR products was
combined with 0.25 μl of ET-ROX 400 marker (GE Healthcare,
Diegem, Belgium) and denaturated for 1 min at 95 °C followed
by rapid cooling to 4 °C in a total volume of 10 μl. The de-
naturated fragments were analyzed on a MegaBACE 500
automated DNA analysis platform (GE Healthcare), according
to the manufacturer's instructions.
2.4. Data analysis
Electropherograms were analyzed using Fragment Profiler
1.2 software (GE Healthcare). Identical isolates were those that
possessed alleles with the same number of repeat units in all
nine loci. Isolates with genotypes that differed in a single locus
were considered to be genetically related. The term unique was
used for genotypes that were only found once in a patient.
3. Results
A. fumigatus isolates from 36 CF patients were analyzed
using the STRAf assay. For 196 of the 204 isolates, a single
genotype was obtained. Eight samples displayed multiple peaks
for all nine loci, indicating to be a mixture of two or more
different A. fumigatus isolates. An overview of the remaining
196 genotypes is shown in Fig. 1 and described below.
Six CF-patients (#1, #6, #8, #9, #17 and #29) harbored only
identical or related A. fumigatus isolates. From five of these
patients, two to four isolates were cultured with a maximum time
interval of 1.5 years. Moreover, patient #29 even showed 7
related isolates over a 3.5 years period. From 7 patients (#3, #7,
#16, #18, #26, #34 and #35) most of the isolates were identical,
since all patients had one or two unique isolates besides the
predominant genotype. Two of the three isolates from patient
#35 were identical, the time interval between these two isolates
was 9.5 years.
In three patients (#25, #28 and #32), identical isolates were
found successively in a period of about one year. The isolates
cultured before or after this period demonstrated unique
genotypes. Patients #27 and #30 also showed identical and
unique isolates. However in these patients during a period in
which identical genotypes were found, also unique genotypes
were present. For example, genotype P from patient #27 was
found in month 11, two years later three other genotypes were
found in the sputum samples of this patient, but after three years
genotype P appeared again.
In the following group of patients, several genotypes were
found more than once. For instance, in patient #20 genotype M
was found twice, followed by genotype N that was also found
twice. In patient #36 a genotype ‘ε’ was found four times in a
period of 9.5 years, whereas second genotype ‘λ’ was observed
Fig. 1. Graphical representation of the genotyping results of A. fumigatus isolates from 36 CF patients. Each patient is represented horizontally (numbers 1–36). The “⁎” symbol indicates patients originating from the
Cystic Fibrosis Center Dekkerswald, patient numbers indicated with “⁎⁎” are from the University of Aachen and with “⁎⁎⁎” from the University Medical Center Würzburg. The arrows indicate one year whereas each
square indicates one month. Unique isolates were depicted with the symbol U, these genotypes were only found once within a patient. Isolates from a patient possessing alleles with the same number of repeat units in all
nine loci are identified by a unique symbol. The ′ symbol after a letter indicates a genotype that differed only in a single locus. The 2,3 and 5 after a symbol showed the number of isolates found within a month, for example
U2 means that two unique isolates were found within one month's period.
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and W) were observed in successive time intervals varying from
one to five months. They alternated with unique genotypes.
Patients #11 and #33 demonstrated the most complex coloniza-
tion patterns. The 9 isolates from patient #11 showed six
different genotypes with two of these genotypes foundmore than
once. The 27 isolates from patient #33 yielded 16 different
genotypes, 6 of themwere found more than once. The remaining
12 patients only showed unique genotypes.
4. Discussion
The A. fumigatus colonization patterns in 36 CF patients were
investigated by typing 204 isolates with the STRAf assay, the
largest study so far. From 196 A. fumigatus a genotype was
obtained, the remaining isolates were mixed genotypes. In
general, four different colonization patterns can be discrimi-
nated. First, continuous colonization patterns were found. The
patients yielded identical or related genotypes for all isolates
over a prolonged period of time, indicating that they were not
able to clear the A. fumigatus isolate. In this collection 17% of
the patients showed colonization with only one genotype. The
second colonization pattern consisted of a predominant
genotype, meaning that most of the isolates were identical.
This group of patients were also not able to clear the
A. fumigatus isolate and were occasionally co-colonized with a
second genotype. This was the case in 19% of the patients. The
third colonization pattern, found in 28% of the patients,
contained genotypes which succeeded each other. These patients
were eventually able to clear the A. fumigatus isolate, but were
easily recolonized. The remaining 36% of the patients yielded
colonization with only unique A. fumigatus isolates, indicating
that these patients were continuously able to clear the fungus
from the respiratory tract.
In some other studies the relation between colonization
patterns of CF patients and clinical symptoms was investigated
[16,18]. In our study population, we did not find an obvious
correlation between colonization pattern and the development of
ABPA, because only three CF patients in this study were
diagnosed with ABPA. In a large multicenter study, 25% of
patients aged 6 years or older harbored Aspergillus [19], yet the
prevalence of ABPA in CF patients in the USA is only 2% [20].
Colonization seems to be related with prophylactic antibiotic use
as a risk factor but there was no relation with lungfunction [21].
Patients using aerolized tobramycin had a higher frequency of
acquisition of Aspergillus than did patients without tobramycin,
but no difference existed in ABPA and fungal pneumonia [22].
To get more insight in relations between colonization patterns
and clinical symptoms, the study should be expanded with a
larger number of CF patients with proven ABPA.
In each center an identical genotype was found in two
different patients and two different patients from two different
centers also showed identical genotypes (data not shown). We
were unable to find a common source of the Aspergillus. The
significance of this finding remains unclear, since the highly
discriminatory STRAf technique can separate a minimum of
99% of unrelated isolates. [11].Molecular fingerprinting of A. fumigatus isolates from the
environment and from clinical samples showed that a high extent
of genetic variability can be found [23]. Therefore typing
techniques with high discriminatory power are necessary to
differentiate isolates from each other. Both the STRAf assay and
the Afut1-RFLP method have shown to fulfill this criterion
[11,23]. Individuals may constantly be exposed to a large variety
of different genotypes; this is in concordance with the 36% of the
patients where only unique genotypes were found. In the
remaining patients identical genotypes were found over longer
periods, which is even more surprising since these patients were
also constantly exposed to different genotypes. In patients #35
and #36 identical genotypes were found for more than 9 years. It
is likely that inside the CF lung a different environment (local
immunosuppression, different pH and growth nutrition) is
present compared to healthy lungs. This may cause a different
growth and virulence of A. fumigatus. Beauvais et al. [24] and
Mowat et al. [25] recently demonstrated that Aspergillus has the
ability to produce a matrix that surrounds hyphae which protects
from the action of antifungals. Future studies may show if the
mucus and the self produced matrix cause a barrier against the
human defense and antifungals and therefore lead to a longer
persistence. However, despite the presence of the viscous
mucus, 36% of the patients in our collection with a unique
colonization pattern were able to clear the fungus from the
respiratory tract.
The colonization patterns of A. fumigatus in CF patients was
comparable with other patient categories. In previous studies
successive A. fumigatus isolates were typed from non CF-
patients. Several patients with invasive aspergillosis [26,27] and
aspergilloma [28] were colonized with multiple genotypes,
whereas other patients harbored unique genotypes. However,
there is a difference between our study and the latter, since
almost all of the isolates were collected within one month.
Symoens et al. [29] collected A. fumigatus isolates from eight
lung transplant recipients. From three of these patients several
isolates were collected over a period of 1 to 3 years also showing
a continuous, predominant and unique type of colonization. To
compare the colonization patterns in CF patients with those with
other underlying diseases, similar studies should be performed
with more non CF patients colonized with A. fumigatus. Such a
group could be the patients with other chronic respiratory
diseases, like bronchial asthma and chronic obstructive pul-
monary diseases, since these patients also are prone to develop
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